GLP-1 receptor agonists in NAFLD - 20/04/17
Abstract |
Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.
Le texte complet de cet article est disponible en PDF.Key words : Steatosis, GLP-1 receptor agonists, type 2 diabetes, Non-alcoholic fatty liver disease, Fibrosis
Plan
Vol 43 - N° S1
P. 2S28-2S33 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.